CurrentCignaPolicy N/A

Oncology (Oral) - Jakafi/Jakafi XR Prior Authorization Policy

Defines Cigna prior authorization and medical necessity criteria for prescription coverage of Jakafi (ruxolitinib) and Jakafi XR for FDA-approved and selected supportive-evidence oncology and inflammatory indications.

Policy Summary

PayerCigna

PolicyOncology (Oral) - Jakafi/Jakafi XR Prior Authorization Policy

Policy CodePolicy N/A

Change TypeMaterial updates (added Jakafi XRnew VEXAS criteriarevised PV and ALL criteria)

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document required clinical and genetic evidence (e.g., UBA1 variant for VEXAS) per indication-specific criteria.

SourceLink

POLICY UPDATE CHANGES

Jakafi XR was added to the policy with the same criteria as Jakafi.

Polycythemia vera criteria updated to add Besremi (ropeginterferon alfa-2b) to the list of prior therapies that must have been tried.

VEXAS syndrome added as an Other Use with Supportive Evidence with specific initial and continuation criteria.

T-Cell lymphoma criteria were added to Other Uses with Supportive Evidence.

Acute lymphoblastic leukemia criteria expanded to include EPOR rearrangement, SH2B3 alterations, or IL7R insertion/deletion as qualifying disease features.

12covered indications listed

1 yearstandard approval

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

VEXAS initial approval

≥18min age (most oncology)

Coverage and Medical Necessity Criteria

FDA-Approved Indications

Covered when ALL of the following are met for each FDA-approved indication:

Acute Graft-Versus-Host Disease: Approve for 1 year if BOTH: (A) patient is ≥ 12 years of age; AND (B) patient has tried one systemic corticosteroid.

Systemic corticosteroid examples provided in policy.

Chronic Graft-Versus-Host Disease: Approve for 1 year if BOTH: (A) patient is ≥ 12 years of age; AND (B) patient has tried one conventional systemic treatment for graft-versus-host disease.

Examples of conventional systemic treatments listed in policy (e.g., cyclosporine, tacrolimus, mycophenolate mofetil, ibrutinib, belumosudil, axatilimab-csfr, pentostatin, rituximab, abatacept, hydroxychloroquine, imatinib).

Myelofibrosis: Approve for 1 year if patient is ≥ 18 years of age (includes primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis).

Polycythemia Vera: Approve for 1 year if BOTH: (A) patient is ≥ 18 years of age; AND (B) patient has tried hydroxyurea, Pegasys (peginterferon alfa-2a), or Besremi (ropeginterferon alfa-2b).

Besremi was added to qualifying prior therapies.

Other Uses with Supportive Evidence

Covered when criteria below are met for select non-FDA or supportive-evidence indications:

Accelerated or Blast Phase Myeloproliferative Neoplasm: Approve for 1 year if BOTH: (A) patient is ≥ 18 years of age; AND (B) patient has at least one disease-related symptom (examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, leukocytosis).

Acute Lymphoblastic Leukemia: Approve for 1 year if BOTH: (A) patient is < 21 years of age; AND (B) patient meets ONE of: (i) the mutation/pathway is JAK-related; OR (ii) the disease has an EPOR rearrangement, SH2B3 alterations, or IL7R insertion/deletion.

Atypical Chronic Myeloid Leukemia: Approve for 1 year if ONE of: (A) patient has a CSF3R mutation; OR (B) patient has a JAK2 mutation (this includes MDS/MPN with neutrophilia).

Chronic Myelomonocytic Leukemia-2 (CMML-2): Approve for 1 year if BOTH: (A) patient is ≥ 18 years of age; AND (B) patient is also receiving a hypomethylating agent (e.g., azacitidine, decitabine).

The policy includes a section titled CONDITIONS NOT COVERED. In the excerpt provided, the section header is present but no specific excluded clinical diagnoses or scenarios are listed; only the product names are shown under that heading in the source text. Providers should therefore rely on the detailed coverage criteria elsewhere in the policy to determine when Jakafi or Jakafi XR meet medical necessity, and be aware that claims lacking a covered diagnosis or appropriate supporting documentation may be denied.

Indication	Covered Regimen / Dosing Reference	Coverage Status
Myelofibrosis (primary, post-polycythemia vera, post-essential thrombocythemia); adults ≥ 18 years	Jakafi (ruxolitinib) or Jakafi XR per FDA‑approved dosing for myelofibrosis; approve for 1 year when criteria met (patient ≥ 18 years). See product labeling for specific starting doses and dose modifications.	Covered
Polycythemia vera; adults ≥ 18 years	Jakafi (ruxolitinib) or Jakafi XR per FDA‑approved dosing for polycythemia vera; approve for 1 year when criteria met (patient ≥ 18 years) after trial of hydroxyurea, Pegasys (peginterferon alfa‑2a) or Besremi (ropeginterferon alfa‑2b).	Covered
Accelerated or Blast Phase Myeloproliferative Neoplasm; adults ≥ 18 years	Jakafi (ruxolitinib) or Jakafi XR per recommended dosing; approve for 1 year when criteria met (patient ≥ 18 years and at least one disease‑related symptom). See NCCN guidance and product labeling for dosing.	Covered
Essential Thrombocythemia; adults ≥ 18 years	Jakafi (ruxolitinib) or Jakafi XR per dosing in product labeling; approve for 1 year when criteria met (patient ≥ 18 years and prior trial of hydroxyurea, Pegasys, or anagrelide).	Covered
Atypical Chronic Myeloid Leukemia / MDS/MPN with neutrophilia; adults ≥ 18 years	Jakafi (ruxolitinib) or Jakafi XR per labeling or guideline dosing; approve for 1 year when criteria met (presence of CSF3R mutation or JAK2 mutation as specified).	Covered
Chronic Myelomonocytic Leukemia‑2 (CMML‑2); adults ≥ 18 years	Jakafi (ruxolitinib) or Jakafi XR in combination with a hypomethylating agent per product labeling/guidance; approve for 1 year when criteria met (patient ≥ 18 years and receiving HMA such as azacitidine or decitabine).	Covered
Myeloid or Lymphoid Neoplasms with Eosinophilia and JAK2 rearrangement; adults ≥ 18 years	Jakafi (ruxolitinib) or Jakafi XR per labeling/guideline dosing; approve for 1 year when criteria met (eosinophilia and tumor with JAK2 rearrangement).	Covered
T‑Cell Lymphoma (including specified subtypes); adults ≥ 18 years	Jakafi (ruxolitinib) or Jakafi XR per product labeling or guideline dosing; approve for 1 year when criteria met (patient ≥ 18 years and meets subtype/prior systemic regimen requirements).	Covered
VEXAS Syndrome — Initial Therapy; adults ≥ 18 years	Jakafi (ruxolitinib) or Jakafi XR per dosing in product labeling; initial approval 6 months when criteria met (pathogenic or likely pathogenic UBA1 variant, prior or current systemic corticosteroid use or contraindication, specialist involvement).	Covered
VEXAS Syndrome — Continuation	Jakafi (ruxolitinib) or Jakafi XR per product labeling; continuation approval 1 year when criteria met (established on therapy ≥ 6 months with objective clinical benefit or symptom improvement).	Covered

Provider Requirements, Authorization, and Billing

Prior Authorization

Prior Authorization Required

Prior authorization is required for Jakafi and Jakafi XR. Typical approval durations: most indications — 1 year; VEXAS initial therapy — 6 months (see VEXAS documentation requirements).

Products requiring prior authorization: Jakafi (ruxolitinib tablets), Jakafi XR (ruxolitinib extended release tablets).
Typical approval durations: 1 year for most FDA-approved and supportive-evidence indications; 6 months for initial VEXAS therapy.

Step Therapy

Prior Therapy / Step Requirements

Step-therapy or prior trial requirements apply for certain indications. Providers must document prior use of required agents (or contraindication) as specified below.

Acute GVHD: patient age ≥12 and has tried one systemic corticosteroid.
Chronic GVHD: patient age ≥12 and has tried one conventional systemic treatment (examples: systemic corticosteroids, cyclosporine, tacrolimus, mycophenolate mofetil, ibrutinib, belumosudil, axatilimab, pentostatin, rituximab, abatacept, hydroxychloroquine, imatinib).

Line of Therapy Requirements

second-line

GVHD acute: Used for steroid-refractory acute GVHD after at least one systemic corticosteroid (patients ≥ 12 years of age).

second-line

GVHD chronic: Used after failure of one conventional systemic therapy for chronic GVHD (patients ≥ 12 years of age).

Molecular and Biomarker Documentation

JAK2 — biomarker requirement

BiomarkerJAK2 rearrangement or JAK2 mutation as specified for qualifying myeloid/lymphoid neoplasms (e.g., myeloid or lymphoid neoplasms with eosinophilia; atypical CML cases may include JAK2 mutation)

Required contextTumor or disease feature must include JAK2 rearrangement for myeloid/lymphoid neoplasms with eosinophilia; JAK2 mutation is an alternative qualifying feature for atypical chronic myeloid leukemia (includes MDS/MPN with neutrophilia)

Age/indication linkageApplies to adult patients (≥ 18 years) for myeloid or lymphoid neoplasms with eosinophilia; atypical CML criteria specify approval when corresponding mutation is present

CSF3R — biomarker requirement

BiomarkerPresence of CSF3R mutation

Indication

Key Terms and Abbreviations

Janus Associated Kinase (JAK) — definition

DefinitionJanus Associated Kinase (JAK): a family of kinases including JAK1 and JAK2 targeted by ruxolitinib

RelevanceJAK pathway alterations (mutations/rearrangements) are qualifying disease features in multiple listed indications (e.g., ALL, atypical CML, neoplasms with eosinophilia)

Therapeutic targetRuxolitinib (Jakafi) is an inhibitor of JAK1 and JAK2 used in covered indications per policy criteria

VEXAS — definition / key term

DefinitionVEXAS (Vacuoles E1 Enzyme X-linked Autoinflammatory Somatic) Syndrome: an autoinflammatory condition associated with somatic UBA1 variants

Diagnostic requirementMolecular genetic testing demonstrating a pathogenic or likely pathogenic UBA1 variant is required for initial therapy approval

Background and Drug Overview

Ruxolitinib (marketed as Jakafi and Jakafi XR) is an inhibitor of Janus Associated Kinases (JAK1 and JAK2). It is FDA‑approved for hematologic and immune-mediated indications including graft‑versus‑host disease (acute and chronic), myelofibrosis, and polycythemia vera. Coverage under this policy follows those FDA‑approved indications and selected supportive‑evidence uses when the specific clinical criteria are met.

Policy Changes and Revision Notes

2026-05-13policy updateLatest

Policy name was changed and Jakafi XR was added to the policy with the same criteria as Jakafi.

2025-12-03addition

VEXAS syndrome was added to 'Other Uses with Supportive Evidence' with defined initial (6-month) and continuation (1-year) approval criteria requiring UBA1 pathogenic/likely pathogenic variant and specialist involvement.

2025-02-19

Policy Summary

PayerCigna

PolicyOncology (Oral) - Jakafi/Jakafi XR Prior Authorization Policy

Policy CodePolicy N/A

Change TypeMaterial updates (added Jakafi XRnew VEXAS criteriarevised PV and ALL criteria)

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document required clinical and genetic evidence (e.g., UBA1 variant for VEXAS) per indication-specific criteria.

SourceLink

On This Page

Essential Thrombocythemia: Approve for 1 year if BOTH: (A) patient is ≥ 18 years of age; AND (B) patient has tried hydroxyurea, Pegasys (peginterferon), or anagrelide.

Myeloid or Lymphoid Neoplasms with Eosinophilia and JAK2 rearrangement: Approve for 1 year if ALL: (A) patient is ≥ 18 years of age; AND (B) patient has eosinophilia; AND (C) tumor has a JAK2 rearrangement.

T-Cell Lymphoma: Approve for 1 year if BOTH: (A) patient is ≥ 18 years of age; AND (B) patient meets ONE of: (i) peripheral T-cell lymphoma; OR (ii) BOTH: (a) patient has one of: T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, hepatosplenic T-cell lymphoma, or breast implant-associated anaplastic large cell lymphoma; AND (b) patient has tried at least one systemic regimen.

Examples of systemic regimens listed in policy (e.g., methotrexate, corticosteroids, cyclosporine, alemtuzumab, fludarabine, mitoxantrone, cyclophosphamide).

VEXAS Syndrome - Initial Therapy: Approve for 6 months if ALL: (i) patient is ≥ 18 years of age; AND (ii) molecular genetic test demonstrates a pathogenic or likely pathogenic UBA1 gene variant; AND (iii) patient has tried or is currently taking a systemic corticosteroid OR systemic corticosteroids are contraindicated; AND (iv) medication is prescribed by or in consultation with an appropriate specialist (rheumatologist, hematologist, dermatologist, immunologist, or autoinflammatory specialist).

Documentation must include molecular genetic test showing pathogenic or likely pathogenic UBA1 variant and evidence of prior or contraindicated systemic corticosteroid use.

VEXAS Syndrome - Continuation: Approve for 1 year if BOTH: (i) patient has been established on the medication for at least 6 months; AND (ii) patient meets at least ONE of: (a) objective measure shows a beneficial clinical response from baseline; OR (b) patient experienced improvement in at least one symptom compared with baseline (examples include decreased joint pain, decreased fatigue, decreased cough/dyspnea, improved ocular symptoms, or improved activities of daily living).

Examples of objective measures include resolution of fever, improvement in skin manifestations, normalization or improvement of serum markers (e.g., CRP, ESR), and/or reduced corticosteroid dose.

Polycythemia vera: patient age ≥18 and has tried hydroxyurea, peginterferon alfa-2a (Pegasys), or ropeginterferon alfa-2b (Besremi).

Documentation Required

VEXAS — Documentation Requirements

For VEXAS initial therapy, submit documentation demonstrating the UBA1 variant and specialist involvement. For continuation therapy, document clinical benefit or objective improvement and treatment duration.

Initial VEXAS therapy requires a molecular genetic test showing a pathogenic or likely pathogenic UBA1 gene variant.
Initial VEXAS: patient must be ≥18, have tried or have contraindication to systemic corticosteroids, and the medication must be prescribed by or in consultation with a rheumatologist, hematologist, dermatologist, immunologist, or other autoinflammatory specialist.
VEXAS continuation: patient must have been established on therapy ≥6 months (or meet initial criteria if restarting) and show benefit by at least one objective measure (e.g., fever resolution, improved skin findings, improved CRP/ESR) or symptomatic improvement vs baseline.

Billing Rule

Billing / Code Mismatch — Denial Risk

Claims lacking a covered diagnosis or appropriate procedure/diagnosis codes per this policy risk denial. Use the most appropriate and specific codes current at the time of submission.

Claims submitted for services not accompanied by covered diagnosis or procedure codes described in the applicable coverage criteria will be denied as not covered.
When billing, providers must use the most appropriate codes as of the effective date of submission; mismatched or non-covered codes increase denial risk.

Qualifies for approval in atypical chronic myeloid leukemia (includes MDS/MPN with neutrophilia) when CSF3R mutation is present

Approval durationTypically 1 year when criteria are met

EPOR, SH2B3, IL7R — biomarker requirements

BiomarkersEPOR rearrangement, SH2B3 alterations, or IL7R insertion/deletion

IndicationQualifies as alternative disease features for Acute Lymphoblastic Leukemia criteria (patients < 21 years) when JAK-related pathway mutation is not specified

Approval durationTypically 1 year when criteria are met

UBA1 — VEXAS requirement

BiomarkerPathogenic or likely pathogenic UBA1 gene variant demonstrated by molecular genetic testing

IndicationRequired for initial therapy approval of VEXAS syndrome (patients ≥ 18 years)

Related documentationMolecular genetic test demonstrating the pathogenic/likely pathogenic UBA1 variant must be provided as part of authorization documentation

Authorization specificsInitial therapy approvals are for 6 months with specialist prescribing/consultation required; continuation criteria include established benefit for 1-year approvals

Polycythemia vera criteria were expanded to add Besremi (ropeginterferon alfa-2b) to the list of prior therapies; T‑cell lymphoma criteria and qualifiers were added/clarified under Other Uses with Supportive Evidence.

2024-03-20addition

Accelerated or blast phase myeloproliferative neoplasm and atypical chronic myeloid leukemia were added to 'Other Uses with Supportive Evidence', with a note that atypical CML includes MDS/MPN with neutrophilia.

2024-02-11revision

Acute lymphoblastic leukemia criteria were expanded to include an approval option when the disease has an EPOR rearrangement, SH2B3 alterations, or IL7R insertion/deletion.